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Abstract
Current treatment of glaucoma relies on administration of daily drops or eye surgery. A gene 
therapy approach to treat steroid-induced glaucoma would bring a resolution to millions of people 
worldwide that depend on glucocorticoid therapy for a myriad of inflammatory disorders. 
Previously, we had characterized a short-term Adh.GRE.MMP1 gene vector for the production of 
steroid-induced MMP1 in the trabecular meshwork and tested reduction of elevated intraocular 
pressure (IOP) in a sheep model. Here we conducted a trial transferring the same transgene 
cassette to a clinically safe vector (scAAV2), and extended the therapeutic outcome to longer 
periods of times. No evidence of ocular and/or systemic toxicity was observed. Viral genome 
distributions showed potential re-inducible vector DNAs in the trabecular meshwork (0.4 vg/cell) 
and negligible copies in six major internal organs (0.00002-0.005 vg/cell). Histological sections 
confirmed successful transduction of scAAV2.GFP to the trabecular meshwork. Optimization of 
the sheep steroid–induced hypertensive model revealed that topical ophthalmic drug difluprednate 
0.05% (durezol) induced the highest IOP elevation in the shortest time. This is the first efficacy/
toxicity study of a feasible gene therapy treatment of steroid-induced hypertension using clinically 
accepted scAAV vectors in a large animal model.
INTRODUCTION
Glucocorticoids, a class of steroid hormones, are potent immunosuppressants and the 
preferred treatment for many inflammatory disorders, including ocular inflammation. A 
wide segment of the worldwide population receives glucocorticoids treatments via various 
routes of administrations, such as oral, topical, systemic injection, inhalation, etc. 
Glucocorticoids have in addition, anti-angiogenic and anti-permeability properties and 
because of that, they are also being widely used in the eye for the treatment of retinal 
diseases, such as macular edema, age-related macular degeneration and diabetic 
retinopathy.1 However, glucocorticoids elicit significant secondary effects in the eye, 
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including the development of cataracts and elevated intraocular pressure (IOP).2 For 
instance, treatment of uveitis with glucocorticoid intravitreal implants results in elevated IOP 
in 78% of the patients, about half of them requiring IOP-lowering surgeries.3 Topically, 
ocular treatment with glucocorticoids produces a dose-dependent IOP increase in 30% to 
40% of the population,4-6 and in 90% of patients with primary open angle glaucoma 
(POAG).7,8 Steroid responsive individuals (termed “steroid responders”) are more likely to 
develop POAG than the non responder counterparts.9 The ocular hypertensive effect of 
glucocorticoids is also significantly greater in older age groups.10 Although it is reversed 
when the steroid treatment is stopped,8,10 this adverse effect of glucocorticoids continues to 
be a major impediment on the clinical management of eye diseases. Because of the essential 
need to use steroids for serious eye disorders, the search for a treatment to control steroid-
induced hypertension is of major importance for the eye.
Glaucoma is a complex optic neuropathy that, if left untreated, results in irreversible 
blindness. Glaucoma is currently the leading cause of irreversible blindness worldwide. It is 
estimated that by 2020 there will be 79.6 million cases of glaucoma11 which will increase to 
111.8 million by 2040.12 The disease is caused by the death of retinal ganglion cells (RGC) 
and degeneration of the optic nerve. It is well-established that elevated IOP is the main risk 
factor associated with the development of the disease.13,14 Physiological and/or elevated IOP 
is determined by the resistance offered to aqueous humor flow by the trabecular meshwork. 
The elevated IOP generated in the anterior segment is transmitted to the back of the eye 
where the sclera senses the pressure fluctuations and exerts a biomechanical strain on the 
optic nerve, contributing to the death of RGCs.15,16 The trabecular meshwork is a 
spongiform soft tissue, located at the angle formed by the iris and cornea, and is formed by 
different types of endothelial-like cells which use a variety of functions to regulate IOP. One 
of its most relevant functions is the one that controls extracellular matrix (ECM) 
composition and deposition levels, which has been shown to have a direct correlation with 
increased aqueous humor flow resistance and glaucoma.17,18
In searching for mechanisms to understand and reduce the hypertensive outcome of 
glucocorticoids, their effects on the trabecular meshwork have been extensively studied. 
Dexamethasone decreases trabecular meshwork phagocytosis,19 increases ECM 
deposition, 20-22 and decreases expression of matrix metalloproteinase 1 (MMP1),23,24 all 
leading to the obstruction of the aqueous humor outflow pathway and to increased IOP. A 
treatment addressing these cellular and molecular adverse consequences could counteract the 
glucocorticoid’s elevated IOP effect. In particular, a long-term, regulated, gene therapy 
treatment could provide an attractive solution to the high number of people affected by the 
high IOP steroid response.
MMP1 is an interstitial collagenase and an integral component of the trabecular meshwork 
scaffold. MMP1 has been the subject of outflow facility studies.25,26 In the trabecular 
meshwork, MMP1 is downregulated by dexamethasone23,24 and upregulated by latanoprost, 
a commonly used glaucoma drug.26-28 Recently we have shown that a glucocorticoid 
inducible MMP1 adenoviral vector Adh.GRE.MMP1 delivered and secreted active MMP1 to 
the trabecular meshwork of human postmortem eyes placed on perfused anterior segment 
organ cultures.29 The vector contained a minimal promoter from the Herpes Simplex Virus 
Borrás et al. Page 2
Gene Ther. Author manuscript; available in PMC 2016 August 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(HSV) thymidine kinase gene (pTAL) followed by the insertion of three tandem copies of 
glucocorticoid response elements (GRE) on the 5’ of the MMP1 cDNA.29 Active protein 
delivery was inducible by dexamethasone and remained silent once the steroid was removed 
from the cultures.29 Further, when the adenoviral inducible vector was injected into the 
anterior chamber of the eye in a sheep model of steroid-induced hypertension, it reduced and 
prevented elevated IOP for approximately 10 days.30
In our quest to develop a potential clinical vector for the treatment of steroid-induced 
glaucoma, and taking into account the need for an extended on and off glucocorticoid 
treatment, here we investigate the same steroid-inducible MMP1 cassette under a safer, 
longer term delivery protocol. We also sought to confirm the effect on different types of 
sheep on site and to investigate newer glucocorticoids drugs. The vectors used in the first 
study, replication-deficient adenovirus vectors, have proven to be very efficient for 
trabecular meshwork delivery studies in vitro and in small and large animals.31-34 However, 
their short length of expression and their immune response precluded them for gene therapy 
based eye treatments. Instead, because of their long-term expression, low immunogenicity 
and success in clinical trials, adeno-associated vectors (AAV) have been the vectors of 
choice for gene therapy of the eye.35,36 Although AAV vectors are unable to transduce 
trabecular meshwork cells,37 our laboratory has shown that their lack of transduction was 
due to the inability of its cells to convert the viral single stranded DNA to double stranded, 
and as consequence, it was overridden by the use of self-complementary AAV (scAAV).37,38 
In monkeys, a single intracameral dose of scAAV2.GFP conferred expression to the 
trabecular meshwork for over two years, with an early onset and a safe clinical profile.37 
Thus, for this study, the same inducible MMP1 cassette was transferred to a scAAV2 viral 
backbone for the assay in a sheep steroid-induced hypertension model.
Animal models of steroid-induced hypertension have been traditionally difficult. The 
requirements of eye drops several times daily for several weeks, together with a response in 
only a given percentage of the animals, posed an important limitation.39 In small animals, 
such as rats, steroid eye drops to both eyes 4× at day resulted in significant elevation of IOP 
after 2-4 weeks.40 Likewise, mice dosed 4× a day showed IOP elevation beginning at 2 
weeks and continuing up to 7 weeks of continuous drops.41 Also in mice, surgical 
subcutaneous implantation of osmotic minipumps induced 30% IOP elevation by 3 weeks 
requiring 20-32 animals to reach significance.42 In large animals, non-human primates 
trained to receive the steroid 4× a day for 4 weeks showed significant IOP elevation starting 
at 1 week. Interestingly, the IOP increase response occurred only in 40% of the monkeys, 
similarly to the response seen in the ophthalmology clinic.43 Instead, sheep exhibit 100% 
response to steroids and thus have been identified as a good animal species for a steroid-
induced ocular hypertension model.44 In addition, because of their docile nature, uncaged 
upkeep and easy handling, steroid treatment and IOP evaluations can be conducted on awake 
animals. Their lower cost than monkeys adds to the advantages of the sheep as a large 
animal model.
Integrating all the past findings together, in this study we investigated the possibility of 
developing a potential clinical treatment of steroid glaucoma using the sheep model and 
scAAV2 vectors. No scAAV vectors had been previously tested for a long-term IOP 
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reduction on a steroid-induced hypertensive animal. This is also the first study of a systemic 
biodistribution of viral particles (VP) after injection of scAAV2 into the anterior chamber of 
the sheep or any other large animal.
Results
Large animal clinical model of steroid-induced glaucoma
Eyes (n=20) in a total of 10 sheep, ages 7 months to 3 years, breeds Katahdin and Corriedale 
were used in this study. As a first approach to evaluate the therapeutic effect of MMP1 on 
steroid-induced elevated IOP, we searched for the optimal steroid-induced model in sheep. 
We compared three types of steroids and three routes of administration, all of which are 
currently used in the clinic for the treatment of ocular diseases. Difluprednate 0.05% 
(Durezol) and Prednisolone acetate 1% (Pred Forte) were administered topically as 0.05 ml 
eye drops three times daily during working hours (8:00 am, 1:00 pm and 4:00 pm) for the 
duration of the experiment. Triamcinolone acetonide 4% (Kenalog-40) was administered as 
single 1 ml injections either to the periocular sub-tenon or intraocular vitreous 
compartments. Pressures were taken one to two times per week. All measurement values 
from each week were averaged and reported as IOP average per week. Eyes used for 
controls were treated with PBS and IOPs assessed at the same time points. Comparison of 
the effects of steroid types and routes of administration on the sheep IOP with time are 
summarized in Figure 1.
The durezol treatment was conducted in a group of n=11 eyes belonging to seven sheep. The 
average baseline value on these eyes was 13.8 ± 0.7 mmHg. We found that the IOP elevation 
effect of durezol occurred very fast and was significantly different from baseline at all time 
points. Two days after the initial dose, IOPs raised 5.6 mmHg, to an average of 19.4 ± 1.1 
mmHg (P = 0.0004). After one week, pressures raised to 20.6 ± 0.4 mmHg (P = 2 × 10−7) 
and further reached 23.0 ± 1.1 mmHg at the end of the second week (P = 5 × 10−7). Three 
and four weeks from the first topical administration, IOP values continued to show a slight 
increase and achieved 23.7 ± 0.8 mmHg (P = 7 × 10−7) and 24.0 ± 0.0 mmHg (P = 5 × 10−7) 
respectively (Figure 1a). At the same time points, eyes treated with PBS drops (n = 4 eyes) 
had IOPs of 13.3 ± 0.5 mmHg (baseline), 12.0 ± 0.0 mmHg (day 2), 12.8 ± 0.4 mmHg 
(week 1), 13.7 ± 0.3 mmHg (week 2), 13.0 ± 1.0 mmHg (week 3) and 12.3 ± 1.2 mmHg 
(week 4) (Figure 1a). At every time point, PBS IOP values were not significantly different 
than those of their own baseline (P = 0.5 to 0.8). Figure 1b shows similar IOP results from a 
representative single sheep whose right eye (OD) was treated with PBS while the left eye 
(OS) was treated with durezol for almost 2 weeks and then stopped. Comparing IOPs from 
both eyes of the same sheep (n=3) also revealed that the steroid did not have any 
contralateral effect.
Although with a positive response, three other steroids’ administration resulted in a lower 
IOP elevation and somewhat more variable response among each of the sheep. Thus, 
treatment with 1% prednisolone (n=6 eyes) was elevated to 15.5 ± 0.6 mmHg at 4 days over 
a baseline of 13.8 ± 0.5 mmHg and (P = 0.09). Eye drops were stopped at 16 days and 
values returned to baseline 24 hours after that time. Administration of kenalog via sub-tenon 
injection (n=2) induced a moderate, albeit significant elevation of IOP at the end of 3 weeks, 
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reaching 17.4 ± 0.4 mmHg over 12.5 ± 0.3 mmHg of their own baseline (P = 2 × 10−9) 
(Figure 1c). When kenalog was injected intravitreally (n = 4) the IOP response was higher, 
reaching 15.8 ± 0.8 mmHg at 3 weeks and 19.6 ± 1.4 mmHg at 4 weeks over their own 
baseline of 12.3 ± 0.4 mmHg (P = 2 × 10−4 and 2 × 10−6 respectively) (Figure 1d).
Altogether, there results indicate that administration of durezol induces the fastest, higher 
and uniformly sustainable steroid-induced elevated IOP and would thus serve as a good 
model for this type of glaucoma in a large animal. Response to the steroid was 100%, with 
highly significant elevation of 6.8 mmHg after one week and 10.2 mmHg after four weeks. 
IOP values after durezol administration exhibited less variability among the eyes. Neither 
age nor breed had a significant effect on the IOP response to durezol. For example, at the 
end of the first week, old Katahdin sheep (n = 5 eyes) exhibited an IOP increase of 21.0 
± 0.6 mmHg over a baseline of 15.2 ± 1.0, while young Katahdin (n = 3) exhibited an IOP 
increase of 19.3 ± 1.2 mmHg over a baseline of 11.7 ± 0.3 (P between old and young = 
0.16). Similarly, old Corriedale sheep (n = 3 eyes) exhibited an IOP increase of 19.8 ± 0.8 
mmHg over a baseline of 14.0 ± 1.2, while old Katahdin exhibited an IOP increase of 21.0 
± 0.6 mmHg over a baseline of 15.2 ± 1.0 (P between Corriedale and Katahdin = 0.2).
Selection of viral vector and combinatory elements
We generated a glucocorticoid inducible scAAV2 vector where the full human MMP1 cDNA 
with Kozak sequences was driven by a 148 bp TATA-like region from the HSV thymidine 
kinase promoter (PTAL),45 commonly used for the assay of transcriptional enhancers. The 45 
bp glucocorticoid response element (GRE) used here contained two directs and one inverse 
repeat in between (repeat sequence: GGTACATTTTGTTCT) inserted in a BglII site 
upstream of the PTAL element. Upstream of the GRE, the vector contains a 153 bp synthetic 
transcription blocker composed of polyA and transcription pause sites for reducing 
background.46 The cassette contained a 33 bp MCS in between the transcription blocker and 
the GRE, and a 247 bp SV40 polyA signal at the 3’ end. This cassette was isolated from an 
adenovirus shuttle vector (pMG17)29 and inserted into a the pHpa-trs-SK plasmid47 
containing the adeno-associated vector (AAV) wild-type and mutated- terminal repeats and 
an additional 196 bp bovine growth hormone (BGH) polyA signal (pMG21). This vector 
comprising an entire transgene expression cassette of 2,249 bp (Figure 2) was used for the 
generation of the self-complementary vector serotype 2 (scAAV2.GRE.MMP1). 
Characterization of the steroid inducibility of the enzyme MMP1 was conducted in vitro by 
infecting primary human trabecular meshwork (HTM) cells with the viral vector and 
analysis of MMP1 expression by TaqMan real time RT-PCR. Addition of 10−7 M 
dexamethasone to the HTM cells induced expression of MMP1 478-fold after 4 days.
Single dose of scAAV2.GRE.MMP1 reduces steroid-induced elevated IOP long-term
To investigate whether a single dose of the inducible MMP1 viral vector was able to 
specifically reduce the steroid-induced elevated IOP long-term, a series of complementary 
experiments were performed in a total of 10 sheep (7-36 months of age) with scAAV2 
viruses, which are known to transduce the trabecular meshwork in vivo for at least 2 years.38 
At different times after steroid-induced elevation (from 4 to 17 days), sheep eyes were 
injected into the anterior chamber with 0.3-1 ×1011 viral genomes (vg) (maximum 100 µl 
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volume) of either scAAV2.GRE.MMP1 (treated group), scAAV2.GFP, or left uninjected 
(control groups). One sheep received adenoviral vectors. Reduction of steroid-induced IOP 
of the treated versus the control was observed in all sheep that received the MMP1-carrying 
vectors. Results are summarized in Figures 3 and 4.
After baselines measurements, the first set, pre-control eyes (n=4) and pre-viral treated (n=4) 
received topical durezol 3× a day to obtain elevation of IOP, which was assigned as time 
zero (T=0). All eyes exhibited IOP increases. In the pre-control group IOP rise was from 
14.2 ± 1.4 mmHg (baseline) to 21.5 ± 0.9 (P = 0.005) and in the pre-viral treated group it 
went from 13.0 ± 1.0 mmHg (baseline) to 21.5 ± 1.3 (P = 0.005). At this time (T=0), eyes 
from one group were injected with the scAAV2.GRE.MMP1 therapeutic vector (treated) 
while the eyes from the second group were left naïve (control). Durezol dosing continued in 
the eyes of both groups to the end of the experiment. Pressures in the control group stayed 
high with values of 21.5 ± 1.0, 25.0 ± 1.5 and 24.0 ± 0.5 mmHg after 1, 2 and 3 weeks 
respectively. Pressures in the viral-treated group were significantly reduced with values of 
18.3 ± 0.3, 16.0 ± 1.5 and 15.4 ± 1.3 mmHg at the same time points (P = 0.002, 5 × 10−8, 
and 1 × 10−10 respectively) (Figure 3).
Additional experiments under different steroids and routes of administration confirmed the 
finding. In one sheep, where topical durezol was stopped after attaining the high response 
and after viral injections (Figure 4a), the scAAV2.GFP-injected control eye IOPs went from 
23.3 ± 0.9 mmHg at T=0 to 20.7 ± 0.3 mmHg after 1 week. In contrast, the therapeutic 
MMP1-treated contralateral eyes IOPs went from 22.7 ± 0.3 mmHg at T=0 to 13.3 ± 0.3 
mmHg at 1 week (viral-treated vs control P = 0.0001) (Figure 4a). In this sheep, 2 weeks 
after stopping the durezol, eyes returned to near baseline in the control eye (17.5 mmHg 
from 16.3 mmHg baseline) or to lower than baseline in the MMP1-treated eye (12.0 mmHg 
from 14.0 mmHg baseline) (Figure 4a). This result indicates that, while in the control eye 
the durezol effect was lasting over two weeks, the MMP1 transgene was able to cause a 
rapid decrease to baseline as soon as one week, and probably earlier.
In another sheep, where pressure elevation in both eyes was induced by intravitreal 
injections of kenalog followed by a viral injection in one eye (Figure 4b), the non viral-
treated, control eye maintained the elevated IOP (24.7 ± 0.9 mmHg) at 2.6 weeks post-
steroid elevation (23.0 ± 0.6 mmHg). At the same time points, the IOP of the contralateral, 
scAAV2.GRE.MMP1-injected eye, was reduced from 23.0 ± 0.9 to 14.0 ± 0.6 mmHg 
(treated vs control P = 0.0001) (Figure 4b). In this animal, IOP reduction was observed at 
0.6 weeks and become significant at 1.2 weeks (treated vs control P = 0.008) (Figure 4b).
The effect of the therapeutic vector in reducing the elevated IOP induced by sub-tenon 
injection of kenalog was tested in an additional sheep with the short-term adenoviral vectors, 
AdhGRE.MMP1 therapeutic and Ad.GFP control (Figure 4c). The post-steroid IOP 
elevation by this route of administration was lower, reaching 18.0 ± 0.5 and 16.8 ± 0.4 
mmHg in the pre-control and pre-viral treated. In the control eye, IOP was maintained to 
18.5 ± 0.4 mmHg at 6 days post-Ad.GFP injection, while in the contralateral MMP1-treated 
eye (AdhGRE.MMP1), IOP was reduced from 16.8 ± 0.4 mm Hg to 14.8 ± 0.3 mmHg at the 
same time period (treated vs control P =4E-5) (Figure 4c). The IOP reduction effect was 
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more pronounced at three days post-viral injection but started to wear off after that time 
(Figure 4c).
Effects on IOP of the control vectors, both the long- and the short-term ones were tested in 
one sheep (Figure 4d). Neither scAAV2.GFP (OD, right eye) nor Ad.GFP (OS, left eye) 
induced IOP changes from baseline at 1 and 2 weeks post-injection. The IOPs of the 
scAAV2.GFP-injected eye were 10.7 ± 0.5 mmHg at baseline and 11.7 ± 0.2 and 11.3 ± 0.7 
mmHg at 1 and 2 weeks respectively (P = 0.1 and 0.7 respectively). The IOPs of the 
Ad.GFP-injected eye were 13.3 ± 0.3 mmHg at baseline and 12.8 ± 0.5 and 11.0 ± 1.0 
mmHg at 1 and 2 weeks respectively (P = 0.5 and 0.2 respectively). (Figure 4d).
All together, these studies demonstrate that the transgene human MMP1 cDNA, delivered by 
scAAV2 gene therapy vectors, is able to counteract the elevated pressure induced by steroids 
in the sheep eyes. Single treatment with the virus also prevented IOP elevation despite 
continuing steroid administration. This efficacy is extended to all steroids and all routes of 
administrations studied. Likewise, the effect is observed in young and older animals, and in 
all the breeds studied. The effect of a single dose lasted for at least 3 weeks, which was the 
last time point studied.
Toxicity effects: clinical signs and histopathology
No adverse clinical signs were observed in the eyes of any of the sheep during the 
experiments. No redness or tearing occurred, and cornea and lens remained clear. No 
formation of cataracts was observed. The morphology of the outflow pathway area was 
assessed by light microscopy in paraffin embedded quadrants of the anterior segment 
sectioned on the meridional plane. Five µm sections from a total of 15 blocks (naïve, durezol 
and durezol/ MMP1-treated eyes) were analyzed. We first observed that the outflow pathway 
area of the sheep eye exhibited a unique shape. The trabecular meshwork tissue is 
meridionally wider than in most described species. It crosses the angle and extends 
inferiorly deep into the iris root, which is thinner to make space for this part of the 
meshwork. The tissue appears to have a more reticular configuration than the higher defined 
beam structure observed in humans, but areas reminiscent of the classical three layers of this 
tissue are distinguishable. The area underneath the Schlemm’s canal appears to be compact, 
while the corresponding trabecular meshwork area shows the appearance of some beams and 
wide spaces in between which become more prominent in the corresponding uveal layer. 
The Schlemm’s canal is present and occasionally looked fragmented (Figure 5, top row). In 
contrast, the outflow pathway of the sheep eye administered topically with durezol looked 
very different. The angle remained open but the intercellular spaces in all layers of the 
trabecular meshwork appeared obstructed due to the expected deposition of excessive 
extracellular material. The whole area looked significantly more compact (Figure 5, middle 
row). After intracameral injections of the therapeutic vector scAAV2.GRE.MMP1, the 
outflow pathway reverted to a morphology which was closer to the naïve animal trabecular 
meshwork. The intercellular spaces became more open as in what could be an indication of 
clearing of the ECM by the action of MMP1. The overall architecture, and the opened 
Schlemm’s canal was preserved. Results from this morphology study provide an 
explanation, and nicely agree with the physiological IOP results obtained above. After the 
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administration of the steroid, an obstructed outflow pathway would lead to an increase 
aqueous humor flow resistance and elevated IOP (Figures 5 and 1), while clearance of the 
extracellular material by the extra levels of delivered MMP1 will allow aqueous humor to 
flow freely and the eye to return to physiological pressure.
Viral genome distribution
Distribution of human MMP1 viral DNA vg in the sheep internal organ tissues after the 
single intracameral injection was analyzed by quantitative TaqMan PCR on six major organs 
(brain, heart, kidney, liver, lung and spleen) from three sheep, where one of the two eyes was 
injected with 8 ×1010 VP of scAAV2.GRE.MMP1 while the contralateral eye was naïve or 
injected with PBS. Tissues were also collected from the different compartments of the eye: 
trabecular meshwork, iris/ciliary body, cornea, and retina. Tissues were collected at necropsy 
at 12, 22 and 30 days post-injection respectively, and stored at −80ºC until use. For the 
genomic DNA (gDNA) determination, standard curves were obtained with sheep 
commercial gDNA (Zyagen, San Diego, CAL, USA) and the single copy human RPPH1 
(Applied Biosystems / Thermo Fisher Scientific, Waltham, MA, USA) probe. Because of the 
reduced homology between the sheep and human genomes, sheep DNA concentrations 
(NanoDrop ND-100 spectrophotometer, Thermo Fisher) were previously adjusted to obtain 
CT values between 26 and 36, which corresponded to concentrations between 180-0.3 ng/µl 
(R square ≥ 0.98). All CT values from each of the sheep gDNA experimental samples fell 
inside the standard curve. For the determination of the number of vg in the sample, the same 
volume from the same tube used for the gDNA determination was hybridized to the 
transgene human MMP1 cDNA TaqMan probe (Applied Biosystems/ Thermo Fisher). The 
standard curve for the vg was obtained with the purified plasmid vector DNA (pMG21) 
adjusted to detect from 68,000 to 6.8 plasmid copies which yielded CT values between 22 to 
37 (R square ≥ 0.98). Results were expressed in vg/ cell. The results of a representative 
sheep shown in Figure 6a-left indicate that negligible to no viral genomes per cell were 
found in the major organs of the three sheep at all time-points after viral injection.
Determination of vg in four main eye tissues was conducted in four sheep also at harvesting. 
Figure 6a-right shows eye tissues results from the same sheep shown in Figure 6a-left. Since 
eyes were injected intracamerally (diagram in Figure 6b-left), the posterior segment (retina) 
showed negligible vg copy numbers/ cell. Likewise, as expected, the anterior segment tissues 
showed detectable number of vg. The highest number was observed in the target outflow 
tissue, the trabecular meshwork, and ranged from 0.4 ± 0.01 vg/ cell (Figure 6a right) to 5.2 
± 0.10 /cell. The iris and cornea tissue values were about ten times lower with ranges of 
0.025 ± 0.0002 (Figure 6a right) to 0.85 ± 0.02 and 0.016 ± 0.002 (Figure 6a-right) to 0.03 
± 0.002 vg/ cell, respectively. Together these results indicate that no detectable viral DNA 
spread to unwanted parts of the body after intracameral injection, while a small amount of 
these genomes are able to persist in the targeted trabecular meshwork tissue.
Fluorescent microscopy of one sheep eye injected with 1×1011 vg of scAAV2.GFP revealed 
intense fluorescence only in the cells of the trabecular meshwork region, confirming the 
targeting of the virus (Figure 6b-right).
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Discussion
Clinical management of steroid induced hypertension requires close monitoring of IOP 
elevations and the concomitant use of glaucoma drugs and/or surgery.48 In some cases, it 
requires cessation of the treatment.48 Although all steroid administrations have been shown 
to lead to steroid-induced glaucoma, the recent popular use of triamcinolone acetonide 
intravitreal injections for macular edema and choroidal neovascularization has resulted in a 
higher incidence of steroid-induced hypertensive cases,49,50 all of them with limited 
treatment possibilities.51 A gene therapeutic approach, based on molecular findings of the 
recent years would offer new options for the management of the disease.
Of the several gene targets that could have been selected for the treatment of steroid-induced 
glaucoma, the gene encoding the MMP1 enzyme proved to be a successful one. In our 
original studies, we showed that MMP1 was highly efficient in reducing steroid-induced 
ECM accumulation and the subsequent obstruction of the trabecular meshwork outflow 
pathway leading to elevated IOP.29 In there, adenoviral MMP1 vectors, designed to be 
inducible only in the presence of the steroid, demonstrated their molecular and functional 
properties in vitro and in perfused human organ cultures,29 and reduced IOP in a steroid 
sheep model at the University of Corrientes (Argentina).30,44 To continue towards the 
development of a potential gene therapy treatment in humans, here we investigated the 
feasibility of establishing the sheep model on site, the induction of elevated IOP by different 
steroids and routes, the efficacy of the inducible MMP1 cassette long-term in a scAAV2 
vector, and the systemic distribution of the viral particle after delivery to the eye.
The use of small animals such as rodents to study steroid glaucoma can provide useful 
molecular information about mechanisms. However the development of a human treatment 
for steroid glaucoma would require large animals whose size, structures, and 
pharmacokinetics would mimic better that of humans. Of the current large animals available 
for eye research, only cow and sheep appeared to be amenable for the study of steroid-
induced hypertension. There was just some moderate IOP response in cats,52 and dogs, and 
in these, only in those dogs with inherited glaucomatous53 (reviewed in39). In the non-
human primate, which is the favorite species for glaucoma studies, the glucocorticoid 
response occurs in just 40% of the animals,43 while in the cow and sheep the response is 
100%.44,54 Of the two, sheep are logistically the easiest animal to keep, because of their 
docile nature, easy training and because of being able to conduct IOP evaluations in non-
sedated animals. The current study using sheep from local North Carolina farmers showed 
no significant difference among the breed or the age of the sheep. The ten sheep used here 
were from the Katahdin and Corriedale breeds and range from 7 months to 3 years of age. 
We did find a difference, though, on the response to different type of steroids and among the 
route of administrations used.
The majority of steroid induced studies in the literature have used dexamethasone (either 
0.1% topical 40,41,43,51 or 4% systemic 42,55) or prednisolone at 0.5%.44 In our studies, 1% 
prednisolone induced elevated IOP at a later time and lower level than it did in the Argentina 
sheep model.30,44 Instead, the newer topical steroid drug durezol resulted in a rapid and 
consistently higher response, with significant average IOP elevation of 5.6 mmHg after 2-4 
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days. Neither topical prednisolone, nor periocular sub-tenon, nor intravitreal kenalog 
injections induced a similarly high IOPs at an early time. The durezol findings in sheep 
appear to correlate with results reported in an uveitis treatment clinical trial where durezol 
IOP elevation response was high and early even in patients considered to be no responders to 
prednisolone.56 In such study, response was higher in children than in adults, while we saw 
no difference between the young and older sheep in our study. The durezol induced IOP 
response increased with time, reaching average elevations of 9.2 mmHg at 2 weeks and 10.2 
mmHg at 4 weeks, when the experiment was terminated. In our sheep, kenalog intraocular 
injections induced also elevated IOP albeit at a slower rate, and to a lower end point. The 
sub-tenon route, in contrast to the quick and high response of the Argentine model,30 
induced an elevation of only 5 mmHg after 3 weeks. The intravitreal route exhibited a 
significant, although small elevation of 1.5 mmHg at 2 weeks and reached 7.3 mmHg at 4 
weeks. Results from a recent 4-years clinical trial at 75 sites on intravitreal triamcinolone 
have reported a mean 34-52 days from time of injection to IOP increases larger than 10 
mmHg,57 which coincides quite well with the result in sheep. In addition, and consistent 
with what it has been reported for prednisolone administrations on the sheep,44 and with a 
chart’s review study on steroid treated patients,58 we did not observe any steroid effect in the 
contralateral eye using durezol. Altogether, these findings plus logistics associated with the 
experimental procedure, including daily maintenance costs, place the sheep durezol model 
as the preferable translational model for steroid-induced gene therapy experiments.
We previously reported in vivo short efficacy of the inducible MMP1 cassette carried in 
adenoviral vectors.30 While adenoviruses contribute to demonstrate proof of principle, they 
do not provide the same stable transduction and lack of toxicity than AAVs. Here, the 
inducible MMP1 transgene inserted in the scAAV2 vector resulted in a reduction of the 
steroid-induced IOP in every sheep treated. After a single dose injection of the therapeutic 
vector, the reduction occurred very quickly and was maintained for at least four weeks, when 
the experiment was terminated. Although we showed efficacy, in this study we did not 
examine amounts of transgene MMP1 RNA in the trabecular meshwork. However, a 
qualitative positive transduction was indirectly assessed by the presence of the GFP 
fluorescence in the sheep trabecular meshwork of an eye injected with the same viral 
serotype carrying the reporter protein. At the present time we don’t know for how much 
longer we could obtain efficacy with a single dose, but based on our published reports 
looking at a reporter GFP in monkeys,38 one would expect to last for at least two years. For 
this study, we used the higher dose allowed by the titer of the virus, that is, we injected the 
maximum volume allowed into the small anterior chamber compartment. That translated 
into using 0.3-1 × 1011 vg per dose. Having seen efficacy, dosing studies will follow to 
determine the minimal effective dose.
Together these results suggest that a gene therapy approach for the treatment of this 
crippling secondary effect would result in a much more effective treatment than the use of 
daily conventional glaucoma drugs, which suffers from the serious compliance issue of the 
older population. The on and off switch inserted in the MMP1 cassette will additionally 
protect the trabecular meshwork from an excessive thinning of the ECM when the steroid is 
not present and ECM build up is not occurring. At the same time, the presence of the switch 
would allow a sole administration to protect the individual from future high IOP responses 
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resulting from future steroid treatments. We have shown that this on and off cycle occurs in 
vitro.29 Experiments that would test the latency in the sheep are in progress.
A literature review of the steroid-induced elevated IOP shows that the IOP elevation seen in 
the clinic appears to peak quite higher than the peak ΔIOP observed on the sheep. In 
patients, ΔIOP ranges have been reported to be from 10 mmHg to up to greater than 30 
mmHg57 while the maximum ΔIOP observed here in sheep was 13 mmHg. We do not know 
whether, when encountered with a higher clinical IOP response, MMP1 would be able to 
reduce the same absolute mmHg values observed here or, as also seen in the sheep, to reduce 
the pressure to closer to baseline. In any case, when the treatment is safe, a 20-30% 
reduction target is quite desirable and the possibility of higher reduction would be an added 
benefit.
Existing and completed clinical trials using AAV viral vectors have established the long-
term safety of ocular gene therapy approach.36 In this study we performed gross clinical 
examination of the eye. Eyes were monitored for signs of inflammation, redness, tearing, 
visual cues and formation of cataracts. No adverse signs were observed and lenses appeared 
clear at euthanization. Neither the topical administration of the steroid, the intracameral 
injection or the therapeutic viral vector caused apparent toxicity. After the steroid treatment, 
the histopathology of the trabecular meshwork showed a thickening of the ECM compared 
to the naïve eye, which agrees with the numerous reports stating increase of ECM deposition 
after exposure to glucocorticoids.20-22 We then observed a less dense ECM after the delivery 
of the MMP1 enzyme, a morphology which appeared to practically revert to the naïve state. 
We also observed a more reticular morphology of the trabecular meshwork region than the 
more beam-like structure seen in humans and primates and which is similar to the one 
observed in bovine.21,59 We see a Schlemm’s canal, which appears to be more elongated 
than the outflow loops described as a Schlemm’s canal substitute in the bovine.21 
Interestingly, we observed that the trabecular meshwork of sheep extends inferiorly and 
seems to occupy an area of the iris root. This morphology had been also observed, albeit not 
described, in angle photographs of the fresh bovine eyes,60 and by personal communication 
(Lütjen-Drecoll). The aqueous humor route of outflow does not seem though to be using the 
iris-extended trabecular meshwork region. Our data showing fluorescence of a scAAV2.GFP 
reporter virus injected in the anterior chamber in vivo, which would be indicative of the 
aqueous humor outflow pathway, shows that the lower trabecular meshwork-iris region is 
not transduced. This could be an indication that this region of the trabecular meshwork has 
no part on the filtering function of the tissue and that all outflow occurs only through the 
“classical” trabecular meshwork site, located at the angle above the iris. Additional 
experiments would need to be conducted though, to further elucidate whether this 
observation could be due to other reasons such as that the virus is not able to transduce the 
lower region.
The systemic biodistribution of the viral particles which were injected into the anterior 
chamber is a key toxicity parameter to determine the safety of the system and thus the 
feasibility of taking the treatment to the clinic setting. The aqueous humor leaves the eye 
through the trabecular meshwork/ Schlemm’s canal and drains into the systemic circulation 
going through, the aqueous veins, episcleral veins, superior ophthalmic vein and superior 
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vena cava, to the heart. We conducted biodistribution studies not only in the heart but in 
lung, liver, spleen, kidney and brain. To calculate the number of viral genomes per cell, we 
developed a protocol using a human MMP1 cDNA probe to quantify the number of viral 
genomes, and a conserved human single copy gene RPPH probe to quantify the number of 
sheep cells in the analyzed sample. Validations were carefully conducted, selecting exon-
spanning (MMP1) and single-exon (RPPH) probes, performing standards curves with the 
MMP1 original plasmid vector, with commercial sheep DNA, and running all reactions at 
the same CT thresholds. Results showed negligible to none viral genomes within the major 
internal six organs collected at euthanasia 22 days after intracameral injection. Inside the 
eye, that is, at the local site of injection, the individually analyzed anterior segment tissues 
were able to retain small number of viral molecules, in particular, the trabecular meshwork. 
This finding would be of great advantage for the planned steroid treatment proposed here. 
Since the MMP1 is only transcribed in the presence of the steroid, a number of silent 
particles remaining inside the trabecular meshwork would be innocuous under standard 
conditions, and could re-start producing the therapeutic transgene in the event of a next 
occurrence of steroid treatment. Our studies thus corroborated the safety of the intraocular 
AAV vectors,61 and reinforce the concept that the availability of a clinically safe proven 
steroid-inducible expression vector would meet requirements to address the adverse ocular 
effects of steroid treatment of patients
MATERIALS AND METHODS
Experimental Animals
All animal procedures were approved by the Institutional Animal Care and Use Committee 
at the University of North Carolina and were conducted in accordance with the tenets of the 
declaration of Helsinki and the Association for Research in Vision and Ophthalmology 
(ARVO) statement on the Use of Animals in Ophthalmic Research. Ten healthy (female) 
sheep (Katahdin and Corriedale breed) between 7 and 36 months of age, and weighing 35 to 
80 kg each, were selected from local farms in the eastern region of USA, for this study. The 
sheep and their eyes were examined to be in good health and tested negative for Q-fever 
upon arrival. Sheep were tagged for individual identification on their ear lobes and kept 
uncaged, allowing them to room freely in a temperature-controlled 140 square feet animal 
room, under 12 h light cycling (7 am to 7 pm). Groups of 2 or 3 sheep were used at all times 
and provided with food and water at libitum. The room was equipped with a showing rail 
containing a head rest (Vittetoe, Inc, Keota, IA) and custom-adjusted to have just one animal 
at a time (Figure 7). The room also counted with enrichment toys to enhance the life of the 
animals. Sheep were adjusted during the first week of arrival with daily petting and training 
to enter the show rail. Animals were very gentle and non-threatening. After each non-
invasive procedure (drops instillation or IOP measurements), sheep were rewarded with 
raisins which they eat out of the operators hand.
Measurement of IOP on Conscious Sheep with the Handheld Tonometer
For the IOP measurements, sheep were guided to the rail one at a time, heads placed on the 
head rest and gently restrained by two loose chains around the neck and snout. This 
arrangement allowed one person to secured the sheep from behind and gently hold the eye 
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lids opened, while the second operator measured the IOP from both sides outside the rail 
(Figure 7). IOPs measurements were conducted by the use of the TonoVet rebound 
tonometer (Colonial Medical Supply, Franconia, NH) positioning the visual axis horizontal 
to the probe and following manufacturer’s recommendations. Before the IOP measurement, 
2 drops of topical 0.5% tetracaine (Bausch & Lomb, Tampa, FL) were instilled. Three sets 
of five measurements were taken on each eye. Only mean values with a SD (expressed as 
percentage of the mean) less than 5% were accepted. All IOP measurements were taken 
between 1 pm and 3 pm every 2-3 days. The whole operation took between 5 to 10 min. 
Baseline IOPs from each eye were taken at one week post-arrival, and two to three times at 
several days before any treatment. Values were averaged and taken as related to the baseline 
of the given eye.
Administration of Steroids
Steroids drops were topically applied by a single operator after guiding the sheep to the rail 
or to the rail corner of the room, secure them from behind and gently opening their eye lids. 
Two to three days after determination of baseline IOPs, two drops of 1% prednisolone 
acetate ophthalmic suspension (Pred Forte, Alcon Laboratories Fort Worth, TX) or two 
drops of 0.05% difluprednate ophthalmic emulsion (Durezol, Alcon Laboratories) were 
topically instilled three times daily at 8 am, 12 pm and 5 pm Monday to Friday and for the 
durations indicated in each of the experiments. In some experiments, the steroid was 
administered to both eyes; in others, only one eye received the steroid.
Ocular hypertension was also induced by periocular injection into the sub-tenon space. After 
topical instillation of two drops of tetracaine 0.5% (Bausch and Lomb), a single 1-ml 
injection of sterile triamcinolone acetonide (Kenalog, 40 mg/mL or 4%; Bristol-Myers 
Squibb, Princeton, NJ) was injected into the sub-tenon space, 5 mm from the limbus using a 
30-G, ½ inch needle.
For intravitreal injections of the triamcinolone, sheep were anesthetized with an 
intramuscular injection of a ketamine/xylazine (Butler Schein, Columbus, OH) cocktail to 
achieve a concentration of 3.5 mg/kg (ketamine) 0.6 mg/kg (xylazine) respectively. 
Occasionally, sheep received a buster of 2 mg/ kg ketamine. A 100 µl of the steroid 
suspension was loaded into a 100 µl 710LT Hamilton syringe (Hamilton, Reno, NV, #80601) 
equipped with a 30 G, ½ inch needle. The needle was inserted at 5 mm posterior from 
limbus at an 80ºC angle towards the posterior pole. Once inside, an assistant pushed slowly 
the plunger to deliver the steroid into the vitreous compartment of the eye.
Construction of the viral vector scAAV2.GRE.MMP1
The three recombinant plasmids used for the generation of the scAAV2.GRE.MMP1 virus 
were: pXX6-80, carrying the adenoviral helper function genes 62, pXX2, carrying the AAV 
virus rep and cap genes to confer serotype 2 62, and pMG21, containing the AAV terminal 
repeats and the transgene expression cassette encoding a steroid-inducible human matrix 
metalloproteinase 1 (MMP1). Plasmids pXX6-80 and pXX2 were obtained from the 
University of North Carolina (UNC) Vector Core facility (http://genetherapy.unc.edu/
services.htm) and pMG21 was generated in our laboratory.
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Plasmid pMG21 was derived from pMG17, which has been described.29 Plasmid pMG17, 
containing a transcription blocker, GRE sequences, a TATA-like PTAL minimal promoter, a 
human MMP1 cDNA and a SV40 polyA, was linearized with NotI, blunted and further 
digested with SalI (Figure 2). The plasmid vector backbone was pHpa-trs-SK,47 which 
contains one wild-type and one-deleted AAV terminal repeat to allow the generation of a 
double stranded AAV (scAAV) upon co-infection of HEK293 cells with pXX2 and 
pXX6-80. This plasmid was provided by the UNC Gene Therapy center.
To make pMG21, the 2,054 bp gel purified 5’-Not1.blunt/ Sal1-3’ fragment from pMG17 
was inserted into the pHpa-trs-SK vector backbone fragment obtained by gel purification of 
a 4,177 bp 5’-KpnI.blunt/ Sal1-3’ fragment DNA. Thus, the resulting pMG21 (6,231 bp) 
contains one wild type and one deleted terminal repeats, the inducible MMP1 expression 
cassette and an additional polyA site from the cloning vector (Figure 2). Triple transfection 
with pXX6-80, pXX2 and pMG21 for the generation of the recombinant virus serotype 2, 
scAAV2.GRE.MMP1, was conducted at the UNC Vector Core as previously described.62 
Viral preparations used in this study had, for controls: 1×1012 vg/ml (scAAV2.GFP) and 
1.6×1012 vg/ml (Ad.GFP), and for the transgene: 2.4×1011 vg/ml (AdhGRE.MMP1) and 
2.5×1011 vg/ml and 7.6×1011 vg/ml (scAAV2.GRE.MMP1).
Intraocular Administration of Recombinant Viral Vectors
Sheep were anesthetized with a ketamine/ xylazine cocktail as indicated above for the 
intravitreal injection of kenalog. While resting on its side on the surgical table, the 
correspondent sheep eye was facing upward and placed under a KL 1500 LCD light source 
(Zeiss, Peabody, MA). The corneas were anesthetized with one drop of 0.5% tetracaine 
(Bausch and Lomb). Up to 100 µl of the viral vector solution was loaded into a 710LT 
Hamilton syringe with a 30-G, ½ inch needle. For the intracameral vector delivery, the 
needle was inserted through the superior cornea a few mms anterior to the limbus, with the 
bevel up to gently reach the center of the anterior chamber. Once inside, the sample was 
delivered by the assistant over 30 seconds and fluid entrance monitored by direct 
visualization. Because of the size of the eye, the injections were performed with the use of 
GL4, 2.5 magnification × 340 mm working distance loupes (Ted Pella, Redding CA) without 
the need of the ophthalmic microscope. The needle was left in place for 1 to 2 min and 
gradually withdrawn to minimize leaking. Topical antibiotic ointment (neomycin 3.5 mg/g, 
polymyxin B 10,000U/g, and bacitracin 400 U/g; Akorn, Lake Forest, IL) was placed on the 
eye, and animals were returned to the pen and kept with their head propped up until recovery 
(between 15 to 30 min).
Histology and Fluorescence Histochemistry
Eyes were enucleated immediately after euthanasia and immersed in fresh 4% 
paraformaldehyde (PFA) for 30 min. Eyes were subsequently dissected above the equator, 
the lens removed and wedge shape specimens containing the trabecular meshwork were 
post-fixed to assess morphology and green fluorescent protein (GFP). For morphology, 
tissue wedges were immersed in 4% PFA/ 2.5% glutaraldehyde/ 0.1M cacodylic acid, pH7.3 
at 4ºC overnight. Specimens were then rinsed in distilled water for 10 min and transferred to 
70% ethanol for delivery to the UNC Histology Core facility for paraffin embedding. 
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Meridional sections 5 μm sections were mounted on microscope slides (Superfrost Plus, 
Thermo Fisher Scientific) and stained with hematoxylin and eosin.
To evaluate GFP fluorescence, tissue wedges were post-immersed in fresh PFA for 4-18 h, 
then consecutively immerse in 10% sucrose (6 hours) and 30% sucrose overnight and 
embedded in Optimal Cutting Temperature (OCT) compound (Tissue-Tek; Sakura Finetek, 
Torrance, Cal). Frozen meridional 10 μm sections were mounted on Superfrost Plus 
microscope slides with Fluoromount G (SouthernBiotech, Birmingham, AL) and GFP 
visualized on a fluorescence microscope (model 1X71, Olympus, Center Valley, PA). Images 
were captured with a digital camera (DP70, Olympus) and accompanying software.
Tissue harvesting, DNA extraction, Quantitative TaqMan PCR and Biodistribution
Animals were anesthetized with a ketamine/ xylazine cocktail (3.5 mg/kg and 0.6 mg/kg 
respectively) and euthanized by overdose of sodium pentobarbital. To assess biodistribution 
of the human MMP1 viral particles, major organ tissue samples (brain, heart, kidney, liver, 
lung and spleen) were collected from three sheep. Likewise, relevant eye tissues (cornea, 
iris, retina, and trabecular meshwork) were dissected from both eyes of four sheep. Tissue 
DNA was purified using a DNeasy tissue kit (Qiagen, Valencia, CAL). Equal aliquots from 
each extracted sample were used to quantify gDNA and vg. Taqman PCR reactions were 
performed in duplicate in a total of 20 μl using 10 μl of either Taqman or Taqman Fast 2× 
universal PCR master mixes (Applied Biosystems/ Thermo Fisher), 1 µl of the 
corresponding probe and 1 to 9 μl aliquots of template experimental sample. Non-template 
controls were run in parallel. Quantifications were performed by TaqMan real time PCR in a 
StepOnePlus instrument (Applied Biosystems/ Thermo Fisher). For the gDNA, samples 
were hybridized to a single copy human RPPH1 single-exon probe (AB, Hs03297761_s1) 
and quantified against a standard curve of RPPH1 with commercial sheep DNA (Zyagen). 
For the vg, samples were hybridized to a human exon-spanning MMP1 cDNA probe 
(Applied Biosystems, Hs0023958_m1) and quantified against a standard curve of hMMP1 
with the plasmid DNA which carried the transgene (pMG17, Figure 2) and had been used 
for the generation of the viral vectors. To allow comparisons among runs, all RPPH1 runs 
were analyzed at a CT at threshold of 0.4 and all MMP1 runs were analyzed at a CT at 
threshold of 0.18. Data is reported as the number of double-stranded vector DNA molecules 
per diploid cell. Amount of sheep genomic DNA (1.7 × 1012 MW) is calculated to be of 168 
ng/ cell.
Data Analysis
Averages values are expressed as mean ± SE. The significance of experimental changes was 
analyzed using Student’s t-test as either paired or unpaired data. For the calculation of P 
values, all technical replicates from all biological replicates were used. The difference was 
considered statistically significant when P-value was < 0.05.
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Figure 1. 
Sheep model of steroid-induced elevated Intraocular Pressure (IOP). Different steroid drugs 
and routes of administration. (a) Durezol (difluprednate 0.05%) and PBS control were 
administered as eye drops 3× daily (n=11 and n=4 eyes respectively). IOP was elevated in all 
durezol-treated eyes and reached 40.6% at 2 days, and 73.9% at 4 weeks (last point). IOP 
from PBS-treated eyes stayed at baseline. (b) a representative sheep was administered with 
durezol in the OS and with PBS in the contralateral OD, same regimen as in A. IOP was 
elevated only in the steroid-treated OS. (c) Kenalog (triamcinolone acetonide 4%) was 
administered by Sub-Tenon injection (n=2). IOP was elevated in both treated eyes and 
reached 21.6% at 1 week and 39.2% at 3 weeks (last point). (d) Kenalog was administered 
by intravitreal injection (n=4). IOP was elevated in two eyes and reached 28.0% at 2 weeks 
and 59.3% at 4 weeks (last point). *: P < 0.0004. OD: right eye, OS: left eye. Eye topical 
administration of Durezol induces the fastest and higher ocular hypertensive response in 
sheep.
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Figure 2. 
Simplified cloning strategy and regulatory elements of plasmid pMG21 used to generate the 
scAAV2.GRE.MMP1 virus. TR, terminal repeat; TB, transcription blocker; MCS, multiple 
cloning site; GRE, glucocorticoid response element; PTAL, HSV thymidine kinase 
promoter; MMP1, human matrix metalloproteinase cDNA; SV40pA & BGHpA, termination 
signals, pMG17, adenovirus shuttle29 and pHpa-trs-SK, terminal repeat containing 
plasmid.47 pMG21 was co-transfected with pXX6-80 and pXX262 to generate the 
therapeutic virus.
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Figure 3. 
Single intracameral dose of scAAV2.GRE.MMP1 reduced durezol-induced hypertension in 
sheep. After baseline readings, sheep eyes (n=8) were treated topically with durezol 3× a 
day to induce elevated IOP (T=0). Four of the eyes were intracamerally injected with 0.3-1 × 
1011 scAAV2.GRE.MMP1 viral particles (blue bars). The other four eyes were left 
uninjected (grey bars). Durezol administration continued after T0 in all eyes for 3 weeks. 
The ΔP-IOP of viral-treated eyes was reduced from 8.5 mmHg (durezol-T0 minus baseline) 
to 5.3 mmHg (durezol-virus minus baseline) (37.6%) at 1 week, and from 8.5 mmHg 
(durezol T0 minus baseline) to 2.4 mmHg (durezol-virus minus baseline) (71.8%) at 3 
weeks. *: P < 0.0005. Viral injected eyes showed reduction of elevated IOP and continued to 
prevent hypertension for the 3 weeks duration of the experiment.
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Figure 4. 
scAAV2.GRE.MMP1’s reduction of IOP is extended to other regimens. (a) when using 
topical durezol to raise the IOP and removing the steroid at post-viral injection, the MMP1-
virus lowered the ΔP surge from 8.7 mmHg (durezol-T0 minus baseline) to less than 
baseline levels (MMP1-virus minus baseline = −0.7 mmHg) in 1 week. At the same time-
point, the ΔP on the control GFP-virus went from 7.4 mmHg to 4.4 mmHg. The effect of the 
durezol slowly declined and began to disappear at two weeks. (b) when using intravitreal 
(IVT) kenalog injection to raise the IOP, the MMP1-virus reduced the ΔP surge from 10.3 
mmHg (kenalog IVT-T0 minus baseline) to 4.6 mmHg (MMP1-virus minus baseline) (55%) 
in 1.3 weeks. At the same time-point, the ΔP on the control non-virus eyes stayed the same 
(ΔP 12.5 mmHg) (0%). At 2.6 weeks, the ΔP in the MMP-1 virus was reduced to 1.8 mmHg 
(82.5% reduction) while that of the control was reduced just to 10.8 mmHg (13.6%). (c) 
when using Sub-Tenon (S-T) kenalog injection, an AdhGRE.MMP1 virus reduction of ΔP 
was short-lived. At 3 days, it went from ΔP 4.6 mmHg to lower than baseline (ΔP −2.0 
mmHg) but the lowering effect started to wear off at 6 days. The control, Ad.GFP did not 
result in any ΔP reduction. (d) both control viruses, (scAAV2.GFP and Ad.GFP) were 
innocuous in normal eyes. *: P < 0.008. OD: right eye, OS: left eye. MMP-1 carrying 
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viruses reduced the steroid-induced pressure under all steroid and route of administrations 
tried.
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Figure 5. 
Morphology of the sheep’s trabecular meshwork after steroid and viral transgene treatments. 
Representative 5 µm light microscopy meridional sections from paraffin embedded sheep 
eye angle tissue, stained with hematoxylin and eosin. (a. Naive) sheep eye dosed 3× a day 
with PBS for 28 days. The trabecular meshwork in sheep is meridionally wider than in other 
animal species and extends inferiorly to the iris root. Although with some reticular 
appearance, traditional layers are distinguishable. Schlemm’s canal is present and 
occasionally looks fragmented. (b. Durezol) sheep eye dosed 3× a day with durezol for 25 
days. Angle is opened and there is a considerable increase of extracellular material 
deposition in all layers. (c. Durezol + scAAV2.GRE.MMP1) sheep eye dosed with durezol 
3× a day for 30 days. Viral vector was injected at day 9. Architecture is preserved, 
Schlemm’s canal is open, and intercellular spaces are cleared from the increased ECM 
deposition. Original magnification 40× (left), 100× (middle), 200× (right). TM: trabecular 
meshwork, SC: Schlemm’s canal, S: sclera, I: iris. Morphology of the steroid-treated 
trabecular meshwork reverts to that of PBS treated after therapeutic vector injection.
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Figure 6. 
Distribution of the MMP1 vector genomes per cell (vg/cell) in tissues collected at the 
termination of the study. (a) major organs (left) and eye tissues (right) DNA from a 
representative sheep injected intracamerally in one eye with 8 × 1010 VP of the MMP1-
vvirus. Taqman probes were single-exon human RPPH (gDNA) and exon-spanning human 
MMP1 cDNA (viral genomes). Lower limit of the vg/cell is calculated based on the minimal 
detection of the TaqMan run (0.8 vg) (b) (left): diagram of the anterior segment of the eye 
showing delivery site and flow direction and drainage of the aqueous humor (right): 10 µm 
meridional cryosection of the trabecular meshwork from a sheep eye injected intracamerally 
with 1 ×1011 VP scAAV2.GFP. TM: trabecular meshwork; I: iris
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Figure 7. 
Composite image of the sheep experimental set up. Sheep are kept uncaged and gently 
guided to the show rail for IOP measurements. IOP is obtained non-invasively in awake 
sheep by the use of a Tono-Vet.
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